Search Results
Cardiovascular risks of residual inflammation despite lipid-lowering | Dr. Paul Ridker
Cardiovascular risks of residual inflammation despite lipid-lowering | Take Away | Dr. Paul Ridker
Inflammation & Atherosclerosis: Where have we been? Where are we going? (Paul M. Ridker, MD) 1/23/20
AHA 2018: The Cardiovascular Inflammation Reduction Trial (CIRT) - Prof Paul M Ridker
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events
Inflammation and Coronary Artery Disease with Dr Paul Ridker
Grand Rounds Interview with Paul M. Ridker, MD (January 23, 2020)
Inflammation, Coronary Artery Disease and hs-CRP with Dr Paul Ridker
400. Cardio-Rheumatology: Targeting Inflammation for Cardiovascular Risk Reduction with Dr. Paul ...
CANTOS Trial Recap with PI Paul Ridker, MD
Paul Ridker: Revolutionizing Cardiovascular Research | Scientist Biography
Highlights on the Great Debate on lipid-lowering therapies: ESC 2022
